Kainos Medicine Inc (284620) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kainos Medicine Inc (284620) has a cash flow conversion efficiency ratio of -0.551x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.97 Billion ≈ $-2.01 Million USD) by net assets (₩5.40 Billion ≈ $3.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Kainos Medicine Inc to measure how many days the company can operate on defensive assets alone.
Kainos Medicine Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Kainos Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kainos Medicine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kainos Medicine Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Econframe Bhd
KLSE:0227
|
0.041x |
|
Kalyani Forge Limited
NSE:KALYANIFRG
|
-0.027x |
|
Times Guaranty Limited
NSE:TIMESGTY
|
-0.017x |
|
Biotoxtech Co. Ltd
KQ:086040
|
-0.010x |
|
Dragonfly Energy Holdings Corp.
NASDAQ:DFLI
|
-2.247x |
|
Next Hydrogen Solutions Inc.
V:NXH
|
-0.352x |
|
Canfor Pulp Products Inc.
TO:CFX
|
-0.064x |
|
Korea Computer Terminal Inc
KQ:089150
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Kainos Medicine Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Kainos Medicine Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 284620 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩1.79 Billion ≈ $1.21 Million |
₩-9.71 Billion ≈ $-6.58 Million |
-5.430x | -348.73% |
| 2023-12-31 | ₩11.75 Billion ≈ $7.96 Million |
₩-14.22 Billion ≈ $-9.64 Million |
-1.210x | -179.71% |
| 2022-12-31 | ₩26.11 Billion ≈ $17.69 Million |
₩-11.30 Billion ≈ $-7.66 Million |
-0.433x | +43.05% |
| 2021-12-31 | ₩12.10 Billion ≈ $8.20 Million |
₩-9.20 Billion ≈ $-6.23 Million |
-0.760x | -23.35% |
| 2020-12-31 | ₩12.35 Billion ≈ $8.37 Million |
₩-7.61 Billion ≈ $-5.16 Million |
-0.616x | -3385.22% |
| 2019-12-31 | ₩9.91 Billion ≈ $6.71 Million |
₩185.74 Million ≈ $125.88K |
0.019x | +937.07% |
| 2018-12-31 | ₩9.83 Billion ≈ $6.66 Million |
₩-22.01 Million ≈ $-14.92K |
-0.002x | +92.18% |
| 2017-12-31 | ₩950.59 Million ≈ $644.20K |
₩-27.23 Million ≈ $-18.45K |
-0.029x | -- |
About Kainos Medicine Inc
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to tre… Read more